Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics (Nasdaq: ABEO) reported that its Compensation Committee granted equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Abeona Therapeutics (Nasdaq: ABEO) reported that its Compensation Committee granted equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4). On August 31, 2026, Abeona approved restricted stock awards covering up to an aggregate of 13,300 shares of common stock for five new hires. These inducement awards vest in three equal annual installments on each anniversary of the grant date, contingent on the employees’ continued employment, and are intended as a material inducement to join the company.

Argus Sep 1 session

+2.14% close to close Open Argus

Details

News Market Reaction – ABEO

On Sep 1, the day this news came out, ABEO closed 2.14% above the previous close.

Data tracked by StockTitan Argus for the Sep 1 session.

Key Figures

Inducement recipients: five individuals Restricted shares: 13,300 restricted shares Annual vesting portion: one-third of shares +1 more

Inducement recipients

five individuals

Employees hired by Abeona

Restricted shares

13,300 restricted shares

Aggregate awards granted August 31, 2026

Annual vesting portion

one-third of shares

Scheduled to vest yearly

Full vesting period

third anniversary

Subject to continued employment

Historical Context

5 past events · Latest: Aug 13

5 events

1. Aug 13

   Q2 earnings report

   24h Move

   -14.9%

   Revenue increased quarter over quarter, but the stock recorded a negative 24-hour reaction.

2. Aug 06

   Earnings call scheduling

   24h Move

   +1.5%

   Company scheduled its second-quarter results conference call and corporate update.

3. Aug 04

   Reimbursement designation

   24h Move

   +6.7%

   CMS granted NTAP status for ZEVASKYN under the Fiscal Year 2027 rule.

4. Aug 03

   Employee inducement grants

   24h Move

   -0.5%

   Abeona granted restricted shares to new employees with three-year vesting.

5. Jul 21

   Treatment center activation

   24h Move

   +0.8%

   Cincinnati Children's became the seventh qualified treatment center for ZEVASKYN.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock equity awards

2 terms

nasdaq listing rule 5635(c)(4) regulatory

"approved in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock equity awards financial

"granted restricted stock equity awards as a material inducement"

Restricted stock equity awards are company shares given to employees or service providers that do not fully belong to the recipient until certain conditions are met, such as time-based vesting or performance targets; if conditions aren’t met the shares can be forfeited. They matter to investors because when those shares vest they increase the number of outstanding shares (dilution) and signal how a company ties employee pay to long-term goals, similar to giving someone a house key that only works after they earn it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

On August 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 13,300 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards is scheduled to vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee are scheduled to be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN^® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.

ZEVASKYN^®, Abeona Assist^®, Abeona Therapeutics^®, and their related logos are trademarks of Abeona Therapeutics Inc.

Contacts:

Investor and Media:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com

Investor:
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What employee inducement equity grants did Abeona Therapeutics (ABEO) announce on August 31, 2026?

Abeona granted restricted stock awards for up to an aggregate 13,300 common shares to five new non-executive employees. According to Abeona, these equity awards were approved as material inducements to employment and are subject to multi-year vesting.

How many Abeona Therapeutics (ABEO) shares are included in the new inducement awards?

The inducement awards cover up to an aggregate of 13,300 restricted shares of Abeona common stock. According to Abeona, these shares are allocated across five newly hired non-executive employees as part of their equity compensation packages.

What is the vesting schedule for Abeona Therapeutics (ABEO) inducement restricted stock awards?

The awards vest in three equal annual installments, with one-third vesting on each grant date anniversary. According to Abeona, full vesting is scheduled by the third anniversary, subject to each employee’s continued employment at the applicable vesting dates.

Why did Abeona Therapeutics (ABEO) grant these inducement equity awards under Nasdaq Rule 5635(c)(4)?

Abeona used Nasdaq Listing Rule 5635(c)(4) to grant equity as a material inducement to employment. According to Abeona, this rule permits equity awards to new employees outside shareholder-approved plans when used as hiring incentives.

Who is eligible for the new Abeona Therapeutics (ABEO) inducement stock grants announced in September 2026?

Five newly hired non-executive employees are receiving the inducement restricted stock awards. According to Abeona, these individuals joined the company recently and the equity grants form part of their overall compensation and retention structure.

What conditions could affect vesting of Abeona Therapeutics (ABEO) inducement awards?

Vesting depends on each employee’s continued employment with Abeona on the scheduled vesting dates. According to Abeona, if an employee is not employed on a vesting date, the remaining unvested restricted shares may not vest as planned.